ACAD
Me parece que no se ha comentado. Otro artículo difamatorio de la CNN. Qué valor hacer esto tras el primero y la respuesta de la FDA:
https://
www.cnn.com/2019/03/08/health/nuplazid-justice-department-invs/index.html
La respuesta de la empresa me ha parecido muy buena, contundente y detallada, además de una amenaza velada:
https://assets.documentcloud.org/documents/5763120/ACADIA-Response-to-CNN-Inquiry-03-07-19.pdf
"To be frank, we are struggling to understand what news you are reporting. The DOJ investigation is ongoing and has been disclosed in our public filings. We have further responded to your statements regarding the Open Payments CMS data and the Boxed Warning below. Based on our further comments below, we find it difficult to see the ‘story’ here,
unless you intend to again present data out of context, mischaracterize data, and present misleading statements.
Our concern is not unfounded.
Previous reporting by CNN included misleading and unsupported statements and implications about NUPLAZID that raised unwarranted safety concerns among patients, their caregivers, and the medical community.
When you published your article last year, it was ultimately the patients and caregivers who suffered the most as many of them no longer sought, opted for or continued treatment with the only FDA-approved drug with a positive benefit/risk profile for hallucinations and delusions associated with PDP. As a result,
a large number of patients were untreated or were left to decide whether to attempt to manage their PDP symptoms with off-label antipsychotic drugs without a proven positive benefit/risk profile."
Parece que el artículo de la CNN esta vez no ha afectado apenas...